De-escalated Therapy Omitting Anthracyclines for Stage I HER2-positive Breast Cancer: A Retrospective Observational Study

SHOGO NAKAMOTO, MASAHIKO IKEDA, SHINICHIRO KUBO, MARI YAMAMOTO and TETSUMASA YAMASHITA

Department of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Fukuyama, Japan

Abstract. Background: It is unclear whether the de-escalated therapy that omits anthracycline-based chemotherapy is as beneficial as standard therapy for patients with stage I human epidermal growth factor receptor 2-positive (HER2+) early breast cancer. Patients and Methods: We retrospectively investigated 95 patients with pathological stage I HER2+ early breast cancer who underwent adjuvant treatment from April 2009 to December 2018. Results: We assessed 45 patients who underwent standard therapy containing anthracyclines, 35 patients who underwent paclitaxel plus trastuzumab (P+TRA group), and 15 patients who underwent trastuzumab monotherapy or no adjuvant therapy; the 5-year invasive disease-free survival rates were 97.8%, 92.9%, and 93.3%, respectively (p=0.255). Adverse events were significantly less frequent in the P+TRA group than in the standard therapy group. Conclusion: In a real-world setting, de-escalated therapy without anthracyclines demonstrated excellent outcomes similar to the standard therapy containing anthracyclines as well as fewer adverse events.

Patients and Methods

Patients. We retrospectively reviewed the data for patients with stage I HER2+ EBC who underwent adjuvant therapy at Fukuyama City Hospital (Japan) from April 2009 to December 2018. We obtained the patients’ medical data from the original hospital records and investigated the patients’ characteristics and outcomes. The hormone receptor and HER2 status were defined according to the American Society of Clinical Oncology/College of American Pathologists guidelines (10, 11). Assessing the pathological reports of surgical specimens, ‘hormone receptor-positive’ defined those with estrogen receptor-positive and/or progesterone receptor-positive, and ‘HER2+’ was defined as a score of 3 in the immunohistochemistry or the presence of HER2 gene amplification by fluorescence in situ hybridization. The physicians decided the adjuvant chemotherapy regimens, including dose modifications, interruptions, and discontinuations, and the patients were divided into three groups according to adjuvant chemotherapy regimen. The standard therapy group (standard group) underwent anthracycline-based regimens...
Table I. Patient characteristics at the time of adjuvant treatment.

|                | Total (n=95) | Standard (n=45) | P+TRA (n=35) | Other (n=15) | p-Value |
|----------------|-------------|----------------|-------------|-------------|---------|
| **Age**        | Median (range) | 58 (35-84) | 58 (35-78) | 74 (29-90) | 0.025^a |
|                | ≥70 Years    | 38 (47.5)  | 10 (22.2)  | 6 (17.1)   | 0.005   |
|                | <70 Years    | 42 (52.5)  | 35 (77.8)  | 29 (82.9)  | 6 (40.0) |
| **Pathologic tumor stage, n (%)** | T1a^b       | 14 (14.7) | 5 (11.1)  | 2 (5.7)    | 0.003   |
|                | T1b          | 23 (24.2)  | 9 (20.0)   | 11 (31.4)  | 3 (20.0) |
|                | T1c          | 58 (61.1)  | 31 (68.9)  | 22 (62.9)  | 5 (33.3) |
| **Histological grading, n (%)** | I           | 11 (11.6)  | 3 (6.7)    | 5 (14.3)   | 0.190^c |
|                | II           | 62 (65.3)  | 27 (60.0)  | 24 (68.6)  | 11 (73.3)|
|                | III          | 21 (22.1)  | 14 (31.1)  | 6 (17.1)   | 1 (6.7) |
| **ER status, n (%)** | Positive  | 53 (55.8)  | 23 (51.1)  | 25 (71.4)  | 5 (33.3) |
|                | Negative     | 42 (44.2)  | 22 (48.9)  | 10 (28.6)  | 10 (66.7)|
| **PgR status, n (%)** | Positive | 35 (36.8)  | 17 (37.8)  | 18 (51.4)  | 0 (0.0)  |
|                | Negative     | 60 (63.2)  | 28 (62.2)  | 17 (48.6)  | 100 (0.0)|
| **Hormone receptor status, n (%)** | Positive | 53 (55.8)  | 24 (53.3)  | 25 (71.4)  | 5 (33.3) |
|                | Negative     | 42 (44.2)  | 21 (46.7)  | 10 (28.6)  | 10 (66.7)|
| **Endocrine therapy, n (%)** | Yes        | 50 (52.6)  | 24 (53.3)  | 22 (62.9)  | 4 (26.7) |
|                | No           | 45 (47.4)  | 21 (46.7)  | 13 (37.1)  | 11 (73.3)|

ER: Estrogen receptor; Other: trastuzumab monotherapy or no adjuvant therapy; P+TRA: paclitaxel plus trastuzumab; PgR: progesterone receptor; Standard: standard therapy including anthracycline-based regimens. ^aKruskal–Wallis. ^bIncluding microinvasive disease. ^cExcluding one unknown patient. Statistically significant p-values are shown in bold.

(epirubicin/cyclophosphamide or fluorouracil/epirubicin/cyclophosphamide) and P+TRA (including three cases without paclitaxel and one case without trastuzumab). The de-escalated therapy groups underwent P+TRA, or trastuzumab monotherapy or no adjuvant therapy (Other group). Lastly, we identified 95 patients with pathological stage I HER2+ EBC who underwent treatment, and we investigated the invasive disease-free survival (IDFS) of these three groups. This retrospective study was approved by Fukuyama City Hospital’s review board (approval number: 524). All procedures that involved human participants were performed in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants in the form of an opt-out on the website included for the study. We assessed adverse events according to Common Terminology Criteria for Adverse Events v5.0 (12).

Statistical analysis. We employed the Kruskal–Wallis test to compare median ages and chi-square test or Fisher’s exact test to compare the proportions of characteristics between the groups. Survival analyses were estimated using the Kaplan–Meier method, and differences between the groups were calculated using the log-rank test. A value of p<0.05 was considered statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) (13).

We defined IDFS as the time from the diagnosis to the first event, according to the standardized definitions for efficacy endpoints (STEEP) system (14): Following ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, death from any cause, contralateral invasive breast cancer, and second primary non-breast invasive cancer. Overall survival (OS) was defined as the time from diagnosis to death from any cause.

Results

Patient characteristics. We identified 95 patients with HER2+ EBC at our institution, with 45 patients assigned to the standard therapy group, 35 to the P+TRA group, and 15 to the Other group. Table I shows the patients’ baseline characteristics. Overall, the median age was 61 years (range=29-90 years), and 58 patients (61.1%) had a T1c tumor, whilst 53 (55.8%) had hormone receptor-positive disease. The median follow-up duration was 61.7 months (range=18.9-123.4) months; 82.4 (range=33.9-123.4) months in the standard therapy group, 38.8 (range=18.9-91.0) months in the P+TRA group and 70.4 (range=19.9-119.9) months in the Other group.

Efficacy. There were four IDFS events in total: one was a distant recurrence (1.1%), and three were deaths without breast cancer recurrence (3.2%). The 5-year IDFS was 97.8% [95% confidence interval (CI)=85.3-99.7%] for the standard group, 92.9% (95% CI=59.1-99.0%) for the P+TRA group, and 93.3% (95% CI=61.3-99.0%) for the Other group (p=0.255) (Figure 1). The 5-year OS was 97.8% (95% CI=85.3-99.7%) for the standard group, 100.0% (95% CI=not reached) for the P+TRA group, and 93.3% (95% CI=61.3-99.0%) for the Other group (p=0.551) (Figure 2).
A dverse events. During the adjuvant therapy, there were significantly fewer adverse events (AEs) in the P+TRA group compared with the standard group. Forty-two patients (93.3%) in the standard group and 14 patients (40.0%) in the P+TRA group experienced grade 3 or 4 neutropenia \((p<0.001)\), and 33 patients (73.3%) in the standard group and 14 patients (40.0%) in the P+TRA group experienced nausea or vomiting \((p=0.003)\). Seven patients (15.6%) in the standard group and none of the patients in the P+TRA group experienced grade 3 left ventricular systolic dysfunction \((p=0.016)\). Other AEs are shown in Table II.

D iscussion

A number of clinical trials and the Cochrane library review demonstrated that the addition of trastuzumab to adjuvant chemotherapy including anthracyclines and taxanes significantly reduced recurrence and mortality (1-6). A meta-analysis that included randomized trastuzumab trials showed that patients with HER2+ tumors measuring 2 cm or smaller derived substantial disease-free survival (DFS) and OS benefit from the addition of trastuzumab to adjuvant chemotherapy (15). A review that included randomized trastuzumab trials showed that patients with small HER2+ tumors also derived a similar benefit in terms of DFS from the addition of trastuzumab to chemotherapy when compared with the overall study (16). Furthermore, retrospective studies have shown a recurrence rate of 5-30% for patients with small node-negative HER2+ EBC and have suggested that these patients might derive a clinically relevant benefit from adjuvant trastuzumab-based therapy (7, 16, 17). However, trastuzumab significantly increases the risk of congestive heart failure (risk ratio= 5.11, 90% CI=3.00-8.72; \(p<0.00001\)), and decreased left ventricular ejection fraction (risk ratio=1.83, 90% CI=1.36-2.47; \(p=0.0008\)) (6). Physicians therefore need to be vigilant for cardiac toxicity, especially in patients with HER2+ EBC and a low risk of recurrence such as stage I. There is a natural expectation that de-escalated therapy should be prescribed for these patients given the desire to prevent cardiac toxicity. However, the efficacy of de-escalated therapy is unknown because previous clinical trials compared the addition of trastuzumab to adjuvant chemotherapy with adjuvant chemotherapy alone. The APT trial recently demonstrated that the combination of paclitaxel and trastuzumab provided excellent outcomes for patients with small HER2+ EBC, with a 3-year DFS of 98.5%, a 5-year DFS of 96.3% and a 7-year DFS of 93.3% (8, 9). However, the APT trial did not have a control arm because no standard of treatment existed at that time for this population. In addition, because of the low incidence of DFS events, it is difficult to conduct a randomized trial. Therefore, we investigated the efficacy of P+TRA compared with standard therapy containing anthracyclines in a real-world setting. Although there were very few IDFS events of distant recurrence (1.1%), our study demonstrated excellent outcomes of P+TRA compared with those of standard anthracycline-containing therapy, and the results were similar to those of the APT trial (9). There are
However, since this was a single-institution study, patients
with stage I HER2+ EBC. Our results for the group containing anthracyclines, and the results support the results of the RESPECT trial (19, 20).

Our study has a number of limitations due to its retrospective nature and being a single-institution study. However, since this was a single-institution study, patients were carefully followed-up and only two (2.1%) were untraceable. In addition, our study allowed us to compare P+TRA therapy omitting anthracyclines with standard anthracycline-containing therapy. As far as we are aware, our report is the first to compare these two groups and to mention the management of HER2+ EBC. We must point out the difference in the follow-up periods between the groups because we had selected the P+TRA regimen in daily practice after the APT study result was published (8). Although our study’s observation period was similar to that reported by many investigators, very few IDFS events occurred, suggesting that the risk of recurrence might be reduced by the de-escalated therapy omitting anthracyclines, which might be an appropriate treatment.

The de-escalated therapy omitting anthracyclines demonstrated excellent outcomes similar to the standard therapy containing anthracyclines in a real-world setting. Cardiac events were significantly less frequent in the P+TRA group. Considering the balance between efficacy and AEs, the de-escalated therapy omitting anthracyclines might be a therapeutic option for stage I HER2+ EBC.

Table II. Adverse events according to treatment.

| Event                        | Total (n=95), n (%) | Standard (n=45), n (%) | P+TRA (n=35), n (%) | Other (n=15), n (%) | p-Value* |
|------------------------------|---------------------|-----------------------|---------------------|---------------------|----------|
| Neutropenia (grade 3/4)      | 56 (58.9)           | 42 (93.3)             | 14 (40.0)           | 0 (0.0)             | <0.001   |
| Nausea/vomiting              | 47 (49.5)           | 33 (73.3)             | 14 (40.0)           | 0 (0.0)             | 0.003    |
| Anorexia                     | 41 (43.2)           | 24 (53.3)             | 17 (48.6)           | 0 (0.0)             | 0.822    |
| Oral mucositis               | 45 (47.4)           | 27 (60.0)             | 18 (51.4)           | 0 (0.0)             | 0.500    |
| Fatigue                      | 65 (68.4)           | 37 (82.2)             | 28 (80.0)           | 0 (0.0)             | >0.99    |
| Constipation/diarrhea        | 59 (62.1)           | 33 (73.3)             | 26 (74.3)           | 0 (0.0)             | >0.99    |
| Dysgeusia                    | 46 (48.4)           | 29 (64.4)             | 17 (48.6)           | 0 (0.0)             | 0.177    |
| Neuropathy                   | 70 (73.7)           | 39 (86.7)             | 31 (88.6)           | 0 (0.0)             | >0.99    |
| Pneumonitis                  | 3 (3.2)             | 2 (4.4)               | 1 (2.9)             | 0 (0.0)             | >0.99    |
| Arthralgia/myalgia           | 25 (26.3)           | 13 (28.9)             | 12 (34.3)           | 0 (0.0)             | 0.634    |
| Eczema                       | 31 (32.6)           | 20 (44.4)             | 11 (31.4)           | 0 (0.0)             | 0.257    |
| LVEF                         | 7 (7.4)             | 7 (15.6)              | 0 (0.0)             | 0 (0.0)             | 0.016    |

LVEF: Left ventricular systolic dysfunction; Other: trastuzumab monotherapy or no adjuvant therapy; P+TRA: paclitaxel plus trastuzumab; Standard: standard therapy including anthracycline-based regimens. *Standard vs. P+TRA therapy. Statistically significant p-values are shown in bold.

Conflicts of Interest

Dr. Nakamoto reports having received personal fees from Chugai Pharmaceuticals, Eisai, and Taiho Pharmaceuticals outside the submitted work; Dr. Ikeda reports having received personal fees from AstraZeneca, Chugai Pharmaceuticals, Daiichi-Sankyo, Eisai, Eli-Lilly, Kyowa Kirin, Pfizer, Nippon Kayaku, Novartis, Mundipharma, Celltrion Healthcare, and Sawai Pharmaceuticals outside the submitted work; Dr. Kubo reports having received personal fees from Eli-Lilly outside the submitted work; Dr. Yamamoto reports having received personal fees from Bayer outside the submitted work. The other authors have no conflicts of interest.
References

1 Cameron D, Piccart-Gebhart MJ, Gelber RD, Proctor M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M and Jackisch C: 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the herceptin adjuvant (HERA) trial. Lancet 389(10075): 1195-1205, 2017. PMID: 28215665. DOI: 10.1016/s0140-6736(16)32616-2

2 Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS and Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16): 1659-1672, 2005. PMID: 16236737. DOI: 10.1056/NEJMoa052306

3 Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martins S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Feihnenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yotbers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN and Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16): 1673-1684, 2005. PMID: 16236738. DOI: 10.1056/NEJMoa052122

4 Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr., Martins S, Mamounas EP, Kaufman PA and Wolmark N: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and SABOP B-31. J Clin Oncol 29(25): 3366-3373, 2011. PMID: 21768458. DOI: 10.1200/jco.2011.35.0868

5 Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinder S, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A and Crown J: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14): 1273-1283, 2011. PMID: 21991949. DOI: 10.1056/NEJMoa0910383

6 Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V and D’Amico R: Trastuzumab-containing regimens for early breast cancer. Cochrane Database Syst Rev 4: CD006243, 2012. PMID: 22513938. DOI: 10.1002/14651858.CD006243.pub2

7 Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA and Hortobagyi GN: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34): 5700-5706, 2009. PMID: 19884543. DOI: 10.1200/jco.2009.23.2025

8 Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shirapa I, Wolff AC, Carey LA, Overmyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ and Winer EP: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2): 134-141, 2015. PMID: 25564897. DOI: 10.1056/NEJMoa1405281

9 Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shirapa I, Wolff AC, Carey LA, Overmyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ and Winer EP: Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 37(22): 1868-1875, 2019. PMID: 30939096. DOI: 10.1200/jco.2019.00066

10 Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittff JL and Wolff AC: American Society Of Clinical Oncology/Collage Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16): 2784-2795, 2010. PMID: 20404251. DOI: 10.1200/jco.2009.25.6529

11 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G and Hayes DF: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society Of Clinical Oncology/Collage Of American Pathologists clinical practice guideline update. J Clin Oncol 31(31): 3997-4013, 2013. PMID: 24101045. DOI: 10.1200/jco.2013.50.9984

12 Common Terminology Criteria for Adverse Events v5.0. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf [Last accessed on 4th October, 2020]
Zujewski JA and Gelber RD: Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: A meta-analysis of the randomized trastuzumab trials. J Clin Oncol 33(24): 2600-2608, 2015. PMID: 26101239. DOI: 10.1200/JCO.2015.60.8620

16 Joerger M, Thurlimann B and Huober J: Small Her2-positive, node-negative breast cancer: Who should receive systemic adjuvant treatment? Ann Oncol 22(1): 17-23, 2011. PMID: 20566473. DOI: 10.1093/annonc/mdq304

17 Vaz-Luís I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP and Lin NU: Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study. J Clin Oncol 32(20): 2142-2150, 2014. PMID: 24888816. DOI: 10.1200/JCO.2013.53.1608

18 Tolaney SM, Trippa L, Barry W, Hu J, Dang C, Yardley D, Isakov S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett M, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz R, Demeo M, Partridge A, Burstein H, Winer EP and Krop I: Abstract gs1-05: Tbcrc 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel (T) In combination with trastuzumab (H) for stage I HER2-positive breast cancerR (BC) (ATEMPT). Cancer Res 80(4_suppl): GS1-05-GS01-05, 2020. DOI: 10.1158/1538-7445.Sabcs19-gs1-05

19 Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y and Ohashi Y: Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol 41(5): 709-712, 2011. PMID: 21355003. DOI: 10.1093/jjco/hyr011

20 Sawaki M, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Taira N, Iwata H, Uemura Y, Ohashi Y and Mukai H: Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial. J Clin Oncol 36(15_suppl): 510-510, 2018. DOI: 10.1200/JCO.2018.36.15_suppl.510

Received September 25, 2020
Revised October 5, 2020
Accepted October 6, 2020